

REVIVE THERAPEUTICS ENTERS INTO ADVISORY AGREEMENT WITH SPINNAKER CAPITAL MARKETS INC.

Toronto, Ontario (March 5, 2015) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSXV: RVV), a clinical-stage company focused on commercializing treatments for gout and orphan drug indications, announced today the appointment of Spinnaker Capital Markets Inc. (“Spinnaker”) as its capital markets and investor relations advisor.

The agreement is for an initial term of three months from March 2, 2015 to June 2, 2015. Spinnaker’s mandate will focus on developing and expanding the network of investors, analysts, and financial intermediaries who are interested in following the Revive growth and investment story. The agreement also provides for a full range of investor relations services for a monthly fee of \$7,500 and is subject to the acceptance of the TSXV.

"We look forward to working with Spinnaker to assist in increasing awareness of Revive and its clinical-stage development programs, more specifically the initiation of the Phase II-A study for the treatment of gout in the U.S., and the expansion of its orphan drug indication pipeline that includes Cystinuria, Wilson disease and Rett syndrome," said Fabio Chianelli, Chief Executive Officer of Revive.

About Spinnaker Capital Markets Inc.

Spinnaker is a Toronto based advisory firm which provides Toronto Stock Exchange and TSXV listed companies with an array of advisory services from investor relations to strategically positioning its portfolio of companies for maximum exposure amongst targeted research analysts, and retail and institutional investors. Spinnaker has long-standing relationships with Canadian, American and European investment banking, asset management and retail brokerage firms with focus on the small to mid-capitalization market segment.

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. (TSXV: RVV) is a clinical-stage company focused on commercializing treatments for gout and orphan drug indications such as Cystinuria, Wilson disease and Rett syndrome. Additional information on Revive is available at www.revivether.com.

For more information please contact:

Fabio Chianelli
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: (905) 605-5535 (ext. 10)
Email: fabio@revivether.com
Website: www.revivether.com

Ali Mahdavi
Managing Director
Spinnaker Capital Markets Inc.
Tel: (416) 962-3300
Email: am@spinnakercmi.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute "forward looking statements", which are not comprised of historical facts. Forward-looking statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could", "would", "will", or "plan", and similar expressions. Specifically, forward looking statements in this news release include, without limitation, statements regarding: the closing of the Offering and the use of proceeds therefrom; the Company's drug research and development plans; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those anticipated or implied in such forward-looking statements. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations. In formulating the forward-looking statements contained herein, management has assumed that business and economic conditions affecting Revive will continue substantially in the ordinary course and will be favourable to Revive, that Revive will be able to obtain all requisite regulatory approvals to commercialize its drug candidates, that such approvals will be received on a timely basis, and that Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect. Factors that may cause actual results to differ materially from those anticipated by these forward looking statements include: uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the Company's ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Revive's Annual Information Form for the period ended June 30, 2014 and Revive's other public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.